Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Teresa I., Pilot-Matias, Tami, Tripathi, Rakesh, Schnell, Gretja, Krishnan, Preethi, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Lu, Liangjun, Asatryan, Armen, Campbell, Andrew, Yao, Betty, Lovell, Sandra, Mensa, Federico, Lawitz, Eric J., Kort, Jens, Collins, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163913/
https://www.ncbi.nlm.nih.gov/pubmed/30154359
http://dx.doi.org/10.3390/v10090462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163913/
https://www.ncbi.nlm.nih.gov/pubmed/30154359
http://dx.doi.org/10.3390/v10090462

Ejemplares similares